These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32875276)

  • 1. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy.
    Vitiello A; Pelliccia C; Ferrara F
    SN Compr Clin Med; 2020; 2(10):1709-1712. PubMed ID: 32875276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
    George PM; Wells AU; Jenkins RG
    Lancet Respir Med; 2020 Aug; 8(8):807-815. PubMed ID: 32422178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
    Ferrara F; Granata G; Pelliccia C; La Porta R; Vitiello A
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1615-1618. PubMed ID: 32594204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?
    Zheng Z; Peng F; Zhou Y
    Chin Med J Pulm Crit Care Med; 2023 Jun; 1(2):77-83. PubMed ID: 37388822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.
    Vitiello A; Ferrara F
    Curr Res Pharmacol Drug Discov; 2021; 2():100056. PubMed ID: 34870154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human-Based Advanced
    Kiener M; Roldan N; Machahua C; Sengupta A; Geiser T; Guenat OT; Funke-Chambour M; Hobi N; Kruithof-de Julio M
    Front Med (Lausanne); 2021; 8():644678. PubMed ID: 34026781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the ACE2/Ang-(1-7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19.
    Morganstein T; Haidar Z; Trivlidis J; Azuelos I; Huang MJ; Eidelman DH; Baglole CJ
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pulmonary fibrosis in patients with COVID-19: A review].
    Chuchalin AG
    Ter Arkh; 2022 Dec; 94(11):1333-1339. PubMed ID: 37167174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel coronavirus pandemic: A clinical overview.
    Kaswa R; Govender I
    S Afr Fam Pract (2004); 2020 Jun; 62(1):e1-e5. PubMed ID: 32633997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SARS-CoV-2 Outbreak: an Epidemiological and Clinical Perspective.
    Wong RSY
    SN Compr Clin Med; 2020; 2(11):1983-1991. PubMed ID: 33015553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Fibrosis after COVID-19: Treatment Prospects.
    Bazdyrev E; Rusina P; Panova M; Novikov F; Grishagin I; Nebolsin V
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: a conundrum to decipher.
    Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic.
    Serra López-Matencio JM; Gómez M; Vicente-Rabaneda EF; González-Gay MA; Ancochea J; Castañeda S
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.
    Edler C; Schröder AS; Aepfelbacher M; Fitzek A; Heinemann A; Heinrich F; Klein A; Langenwalder F; Lütgehetmann M; Meißner K; Püschel K; Schädler J; Steurer S; Mushumba H; Sperhake JP
    Int J Legal Med; 2020 Jul; 134(4):1275-1284. PubMed ID: 32500199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 patients may become predisposed to pulmonary arterial hypertension.
    Suzuki YJ; Nikolaienko SI; Shults NV; Gychka SG
    Med Hypotheses; 2021 Feb; 147():110483. PubMed ID: 33444904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies.
    Sanguedolce F; Zanelli M; Froio E; Bisagni A; Zizzo M; Ascani S; Stallone G; Netti S; Ranieri E; Falagario U; Carrieri G; Cormio L
    Crit Rev Clin Lab Sci; 2021 Dec; 58(8):563-575. PubMed ID: 34236278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.